Risk factors of pancreatitis after endoscopic retrograde cholangiopancreatography in patients with biliary tract diseases

Table 1 Comparison of baseline data between the two groups

Baseline data	Control group (n = 405)	Study group (n = 75)	X²	P
Age (%)			5.334	0.021
< 60	128(31.6)	34(45.3)
≥ 60	277(68.4)	41(54.7)
Sex (%)			13.516	<0.001
Male	254(62.7)	30(40.0)
Female	151(37.3)	45(60.0)
History of pancreatitis (%)			23.069	<0.001
No	373(92.1)	55(73.3)
Yes	32(7.9)	20(26.7)
History of diabetes (%)			0.889	0.346
No	321(79.3)	63(84.0)
Yes	84(20.7)	12(16.0)
History of hypertension (%)			0.026	0.872
No	277(68.4)	52(69.3)
Yes	128(31.6)	23(30.7)
History of ERCP (%)			1.504	0.220
No	285(70.4)	58(77.3)
Yes	120(29.6)	17(22.7)
Indication for ERCP (%)
Choledocholithiasis	203(50.1)	46(61.3)	3.185	0.074
biliary stricture	0(0)	1(1.3)	-	0.156
pancreatitis	39(9.6)	12(16.0)	2.704	0.100
cholangeitis	216(53.3)	45(60.0)	1.134	0.287
Others	110(27.2)	17(22.7)	0.657	0.418
History of cholecystectomy (%)			0.558	0.455
No	358(88.4)	64(85.3)
Yes	47(11.6)	11(14.7)
History of choledocholithiasis (%)			5.612	0.018
No	288(71.1)	43(57.3)
Yes	117(28.9)	32(42.7)
Total bilirubin	78.93 ± 95.77	65.85 ± 92.76	1.091	0.276
Triglyceride	1.52 ± 0.85	1.45 ± 0.68	0.751	0.453

Count data are expressed as n (%), and measurement data as mean ± SD. ERCP, Endoscopic retrograde cholangiopancreatography; study group, patients developed pancreatitis after ERCP; control group, patients did not develop pancreatitis after ERCP.

ISSN: 1471-2482